LYNPARZA is approved as a maintenance therapy for BRCA-mutated ovarian cancer after the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapy.

LYNPARZA could give adults with a BRCA mutation more time progression free

A clinical study included 295 patients with an inherited BRCA mutation and ovarian cancer that had returned and responded to platinum-based chemotherapy. 196 patients took LYNPARZA and 99 patients took placebo.

LYNPARZA lowered the risk of disease progression or death by 70% compared with placebo.

70%

Lower risk of disease progression or death

Adults on LYNPARZA were alive and didn’t see their cancer progress for a median of more than 1.5 years (19.1 months) vs less than half a year (5.5 months) on placebo.

LYNPARZA

19.1 Months 19.1 Months

19.1 months

PLACEBO

5.5 Months 5.5 Months

5.5 months

89 out of 196 patients on LYNPARZA were alive and did not see their cancer grow or return for a median of more than 1.5 years (19.1 months), compared with 19 out of 99 patients on placebo who did not see their cancer grow or return for a median of 5.5 months.

Talk to your doctor about a BRCA test to find out if you're eligible for LYNPARZA.

Adults with or without a BRCA mutation

Another study evaluated 265 patients with or without a BRCA mutation whose ovarian cancer had returned and responded to platinum-based chemotherapy. 136 patients took LYNPARZA and 129 patients took placebo.

LYNPARZA reduced the risk of disease progression or death by 65% compared with placebo.

Adults on LYNPARZA were alive and didn’t see their cancer progress for a median of 8.4 months vs 4.8 months on placebo.

LYNPARZA

5.5 Months 5.5 Months

8.4 months

PLACEBO

5.5 Months 5.5 Months

4.8 months

76 out of 136 patients on LYNPARZA were alive and did not see their cancer grow or return for a median of 8.4 months, compared with 35 out of 129 patients on placebo who did not see their cancer grow or return for a median of 4.8 months.